• By ICR Secretariat
  • Posted Wednesday, April 5, 2023

Sanofi, Regeneron surge as Dupixent scores in COPD trial


  • An anti-inflammatory drug from Sanofi and Regeneron succeeded in a Phase 3 clinical trial in chronic obstructive pulmonary disease, giving the medicine, Dupixent, a chance to become the first biologic treatment approved for the condition.